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Abstract 
Objective. We have tried to determine what baseline variables are responsible for 
remission induction at 6 months in rheumatoid arthritis (RA) patients treated with 
etanercept of Japanese population in unselected patients.  
Methods. One hundred forty-one patients with RA, etanercept being administrated, 
were registered. Thirty-four patients were started as etanercept monotherapy, 60 patients 
as cotherapy with methotrexate (MTX) (MTX cotherapy) and 47 patients as cotherapy 
with other non-MTX nonbiologic disease modifying antirheumatic drugs (DMARDs) 
(non-MTX cotherapy), respectively. None of the patients were treated with both MTX 
and non-MTX nonbiologic DMARDs at entry. The outcome was set as the achievement 
of Disease Activity Score (DAS) 28-ESR remission at 6 months. We have examined the 
association of gender, DAS at baseline, MTX cotherapy at baseline, non-MTX 
cotherapy at baseline and prednisolone use at baseline with the achievement of 
remission at 6 months by logistic regression analysis. 
Results. All of the subjects were classified as high disease activity (N=109) or moderate 
disease activity (N=32) at entry. One hundred twenty out of 141 patients (85.1%) 
continued the treatment of etanercept at 6 month. Continuation rate was statistically 
high in MTX cotherapy (93.3%) as compared with etanercept monotherapy (73.5%), 
and tended to be higher than non-MTX cotherapy (85.1%). Logistic regression analysis 
identified that MTX cotherapy at entry and moderate disease activity at entry are 
independent variables toward remission induction at 6 month. Accordingly, 
DAS28-ESR at 6 month was significantly low in MTX cotherapy as compared with 
etanercept monotherapy or non-MTX cotherapy. To a lesser extent, DAS28-ESR of 
non-MTX cotherapy at 6 month was lower than etanercept monotherapy.  
Conclusions. In this study of unselected patients, the use of MTX and moderate disease 
activity at entry was associated with a higher likelihood of response toward etanercept. 
Non-MTX nonbiologic DMARDs may be alternative in patients with RA to being 
administrated of etanercept who are intolerant to MTX.  
Introduction 
Randomized controlled trials of the anti-tumor necrosis factor  (anti-TNF ) therapies 
including etanercept in rheumatoid arthritis (RA) have shown etanercept to be superior 
to placebo and to methotrexate (MTX) monotherapy in patients with active RA (1, 2). 
The trial of Etanercept and Methotrexate with Radiografic Patient Outcomes (TEMPO) 
study compared etanercept with MTX, starting each as new monotherapy or both as 
combination therapy, and found the combination to be superior to either drug alone (3). 
However, the majority of patients in clinical practice who will receive etanercept will 
already received nonbiologic disease modifying antirheumatic drugs (DMARDs) 
including MTX yet have ongoing disease activity. In addition, the dosage as well as 
kinds of nonbiologic DMARDs on the “real-world” of RA in Japan are different from 
the western countries, thus, an evidence of “real-world” effectiveness of etanercept 
should be established in Japanese patients.  
  In this study, we have investigated whether baseline variables at treatment initiation 
are associated with clinical response to the treatment of etanercept, and shown that 
MTX cothrepay as well as the moderate disease activity are predictive for remission 
induction at 6 month.  
 
Patients and Methods 
Patients. Patients were recruited from Unit of Translational Medicine, Department of 
Immunology and Rheumatology, Graduate School of Biomedical Sciences, Nagasaki 
University, Sasebo Chuo Hospital, Kurume University School of Medicine, Gotokai 
Hospital, The Japanese Red Cross Nagasaki Atomic Bomb Hospital, Nagasaki Citizen 
Hospital, Isahaya General Hospital, NHO Ureshino Medical Center and NHO Nagasaki 
Medical Center. The written form of the informed consent, which is approved by the 
above hospitals, was obtained from each patient. The patients who received with both 
MTX and non-MTX nonbiologic DMARDs at entry were omitted from this 
observational study. At entry, 152 patients were recruited, however, 11 patients at 
evaluation were excluded by combination use of MTX and non-MTX nonbiologic 
DMARDs. Thus, data of 141 RA patients, who received etanercept for 6 month, were 
collected. All of the patients fulfilled 1987 criteria of the ACR for RA (4). Disease 
activity was evaluated by Disease Activity Score (DAS) 28-ESR and all of the patients 
were high (N=109) or moderate disease activity (N=32) at entry. Thirty-four patients 
were entered as etanercept monotherapy, 60 patients as cotherapy with methotrexate 
(MTX) (MTX cotherapy) and 47 patients as cotherapy with other non-MTX 
nonbiologic DMARDs (non-MTX cotherapy), respectively. Non-MTX nonbiologic 
DMARDs included leflunomide (N=8), tacrolimus (N=5), salazosulufapyridine (N=8), 
mizoribine (N=10), bucillamine (N=11), D-penicillamine (N=1), tiopronin (N=10), 
cyclosporine A (N=3) and actarit (N=2), respectively. Although MTX cotherapy group 
did not receive other nonbiologic DMARDs at entry, some of non-MTX cotherapy 
patients received 2 (tacrolimus ＋ salazosulufapyridine; 1 patient, leflunomide ＋
mizoribine; 1 patient, salazosulufapyridine＋mizoribine; 2, bucillamine＋tiopronin; 4, 
mizoribine＋ actarit; 1) or 3 kinds (bucillamine＋ tiopronin＋D-penicillamine; 1, 
bucillamine＋tiopronin＋cyclosporine A; 1) of nonbiologic DMARDs. 
 
Statistical analysis. Distribution of baseline variables were examined by 
Mann-Whitney’s U test, Kruskal-Wallis test and Chi-Square test. Logistic regression 
analysis was performed to investigate a relationship between baseline variables and 
clinical efficacy at 6 months. Clinical efficacy was set in the present study as the 
achievement of DAS28-ESR remission at 6 months (less than 2.6). Etanercept 
continuation rate at 6 month was also examined. DAS28-ESR at 6 months was judged 
by the last observation carried forward (LOCF) approach. Baseline variables were 
gender, DAS28-ESR at baseline ［High disease activity (≧5.1) versus moderate disease 
activity (3.2≦DAS28-CRP＜5.1)］, MTX at initiation (MTX cotherapy), cotherapy 
with non-MTX nonbiologic DMARDs (non-MTX cotherapy) at initiation and 
prednisolone at initiation. Prednisolone ＞5 mg/day at intiation was also examined for 
logistic regression analysis. P value less than 0.05 is considered to be significant. 
 
Results 
Baseline variables of 141 patients with RA treated with etanercept for 6 month and drug 
survival at 6 month 
Table 1 summarized the data. Most of the patients were established disease whose mean 
disease duration was 10.4 years at baseline. None of the patients were received biologic 
DMARDs (infliximab, adalimumab, tocilizumab) other than etanercept during the 6 
month. All of 141 patients expressed high disease activity (N=109) or moderate disease 
activity (N=32) at baseline (Table 1). Baseline variables, including age, gender, duration 
of disease, MTX use at initiation and prednisolone use at initiation were not different 
between high and moderate disease activity (Table 1). At the end of 6 month follow-up 
period, 120 patients continued etanercept. The continuation rate at 6 month was 93.3% 
(56 out of 60 patients) in MTX cotherapy, 85.1% (40 out of 47 patients) in non-MTX 
cotherapy and 73.5% (25 out of 34 patients) in etanercept monotherapy (p=0.004; MTX 
cotherapy vs etanercept monotherapy, p=0.09; MTX cotherapy vs non-MTX cotherapy). 
The reasons for discontinuation, judged by each physician, are the followings: In 
etanercept monotherapy group, one patient discontinued by lack of efficacy, skin 
eruption, angina pectoris or perforation of sigmoid colon. Six patients discontinued by 
respiratory tract infection. One patient complicated with 2 adverse events at the 
discontinuation. In non-MTX cotherapy group, one patient discontinued by lack of 
efficacy, itching of skin, compression fracture of the spine or sepsis. Three patients 
discontinued from respiratory tract infection. In MTX cotherapy group, one patient 
discontinued by elevation of liver enzymes or respiratory tract infection. Two patients 
discontinued by skin eruption.      
 
MTX cotherapy and moderate disease activity at initiation are independent predictors 
for DAS28-ESR remission at 6 months 
Table 2 shows the data of logistic regression analysis. As shown in Table 2A, MTX 
cotherapy and moderate disease activity at baseline were independent predictors toward 
remission induction at 6 month. The similar results were obtained if the dosage of 
prednisolone at initiation was limited as ＞5 mg/day (Table 2B). Other variables of 
gender, non-MTX cotherapy, prednisolone at initiation did not reach to statistical 
significance. Accordingly, baseline variables among MTX cotherapy, non-MTX 
cotherapy and etanercept monotherapy were similar except for the slight difference of 
age at initiation (Table 3). We have examined the change of DAS28-ESR during 6 
month. DAS28-ESR at initiation did not differ among the 3 treatment groups, however 
as expected, DAS28-ESR at 6 month was significantly low in MTX cotherapy as 
compared with etanercept monotherapy (p < 0.0001) and non-MTX cotherapy 
(p=0.009) (Figure 1). In addition, DAS28-ESR at 6 month of non-MTX cotherapy was 
statistically low as compared with etanercept monotherpy (p=0.04) (Figure 1). Rate of 
DAS28-ESR remission at 6 months was 26.7% (16 our of 60) in MTX cotherapy, 12.8% 
(6 out of 47) in non-MTX cotherapy and 8.9% (3 out of 34) in etanercept monotherapy , 
which was significantly high in MTX cotherapy (P=0.03, MTX cotherapy vs etanercept 
monotherapy).   
 
Discussion 
The results of this study support the benefit of the combined use of etanercept with 
MTX, which performed better than etanercept alone or etanercept in combination with 
non-MTX nonbiologic DMARDs. This is a reasonable, but provides an important 
information in clinical practice in Japan since the MTX dosage is quite low and 
non-MTX nonbiologic DMARDs is different as compared with western countries. The 
trend of non-MTX cotherapy is better than etanercept monotherapy is also similar to the 
observational study of western countries described by Hyrich et al (5) and Kristensen et 
al (6). All of the RA patients, etanercept being introduced, will not be tolerant to 
nonbiologic DMARDs, however, physicians are needed to recognize that MTX and, to a 
lesser extent, non-MTX nonbiologic DMARDs improve the efficacy of etanercept.   
  Male gender is selected for the predictor of remission induction by TEMPO study 
whereas is not found in the present study. MTX dosage is clearly different between the 
two groups and TEMPO study does not include RA patients treated with non-MTX 
nonbiologic DMARDs, which may explain the different results.  
  Systemic administration of low dose glucocorticoids are effective in relieving short 
term signs and symptoms in patients with RA although its role in the disease outcome 
remains to be obscure (7). This study does not provide an efficacy of low dose 
glucocorticoids in patients with RA treated by etanercept. Preferably, treatment of the 
RA with glucocorticoids is temporary because of the risk of side effects and lack of the 
add-on effect to etanercept.  
  TEMPO study has identified lower disease activity at initiation is more likely to 
reach remission. Accordingly, moderate disease activity at entry is predictive toward 
remission induction as compared with the patients of high disease activity. Similar 
results are also obtained in Japanese RA patients treated with infliximab (8), suggesting  
that this demography may be common indicators for good therapeutic response of 
DMARDs in patients with RA. 
  There are limitations to comparing treatment outcomes based on observational data, 
since the decision to treat patients is not random, but is highly dependent on a number 
of factors, such as disease severity, patient choice and compliance, and comorbidities. 
Similary, the decision to stop therapy because of inefficacy or adverse events in this 
“real-world” study was at the direction of the rheumatologist and was not subject to 
strict protocol. However, we still found a significant difference between the combined 
use of etanercept plus nonbiologic DMARDs, especially MTX as compared with 
etanercept monotherapy and moderate disease activity at initiation to the achievement of 
good therapeutic efficacy. Our data provide clinical benefit for etanercept user in 
clinical practice. 
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Figure Legends 
Figure 1. Change of DAS28-ESR in patients with RA treated by MTX cotherapy, 
non-MTX cotherapy and etanercept monotherapy during 6 month. DAS28-ESR after 
entry was calculated by LOCF approach. DAS28-ESR at entry were not different 
among MTX cotherapy, non-MTX cotherapy and etanercept monotherapy. At 6 month, 
DAS28-ESR was significantly decreased in MTX cotherapy as compared with 
etanercept monotherapy and non-MTX cotherapy. In addition, DAS28-ESR at 6 month 
of non-MTX cotherapy was statistically low as compared with etanercept monotherpy. 
**p < 0.0001: MTX cotherapy vs etanercept monotherpy * p=0.009: MTX cotherapy vs 
non-MTX cotherapy.  #p=0.04: non-MTX cotherapy vs etanercept monotherapy. The 
differences were examined by Mann-Whitney’s U test.  
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Baseline characteristics Baseline DAS28-ESR
Table 1. The characteristics of RA patients at entry
  
All patients High group Moderate Group p value
No. of patients N = 141 N = 109 N = 32 -
age, y.o., mean±S.D. 56.8±13.9 56.0±14.3 59.5±11.9 p = 0.22
gender (male/female) 32/109 24/85 8/24 p = 0.73*
duration of disease 10.4±8.9 9.9±8.7 12.0±9.4 p = 0.47    
DAS28-ESR, mean±S.D. 5.85±1.06 6.28±0.73 4.39±0.55 p < 0.01
High (>5.1) N = 109 [77.3%] N = 109 - -
Moderate (3.2-5.1) N = 32 [22.7%] - N = 32 -
MTX use at baseline
(Yes/No)
60/81 49/60 11/21 p = 0.20*
PSL use at baseline N=124[87.9%] N=99[90.8%] N=25[78.1%] p = 0.06*
PSL>5mg at baseline N=72 [51.1%] N=57[52.3%] N=15 [46.9%] p = 0.37*
Baseline characteristics, including age, gender, duration of disease at baseline, MTX use at 
baseline and prednisolone use at baseline were not different between DAS28-ESR high 
(N=109) and DAS28-ESR moderate patients (N=32). The distribution is characterized by 
Mann-Whitney’s U test or ＊Chi-Square test as described in the text.
Table 2. Logistic regression analysis to estimate remission induction by etanercept  
A. Variables: gender, MTX at initiation, nonbiologic DMARDs
other than MTX at initiation, prednisolone at initiation, DAS28-ESR
Gender 
comparison odds ratio 95% C.I.
male/female 0.76 0.22 – 2.60
Baseline variables p value
0.66
MTX yes/no 4.65 1.13 – 19.09




yes/no 0.56 0.16 – 2.01Prednisolone 
moderate/high 4.08 1.43 – 11.55
0.38
0.008
B. Variables: gender, MTX at initiation, nonbiologic DMARDs
other than MTX at initiation, prednisolone >5 mg/day at initiation, DAS28-ESR
comparison odds ratio 95% C.I.Baseline variables p value
Gender 
MTX 
male/female 0.70 0.20 – 2.43
yes/no 4.68 1.14 – 19.16
0.57
0.03
i i i ( )
yes/no 0.46 0.17 – 1.24
DMARDs other than MTX yes/no 1.47 0.31 – 7.05




MTX use at initiation and moderate disease activity at baseline are predictive for remission induction. 
D sease act v ty DAS28-ESR  mo erate g 4.27 1.52 – 12.00 0.006
Table 3. Comparison of baseline characteristics among MTX cotherapy, Non-MTX






No. of patients N = 60 N = 47 N = 34 -
age, y.o., mean±S.D. 54.4±13.2 59.5±12.3 57.1±16.7 p = 0.046
gender (male/female) 12/48 9/38 11/23 p = 0.30
duration of disease 9.3±7.9 11.4±9.0 10.9±10.4 p = 0.69
DAS28-ESR, mean±S.D. 5.97±1.01 5.87±1.04 5.58±1.13 p = 0.45
Hi h (>5 1) N 49 [81 7%] N 37[78 7%] N 23[67 6%] 0 29g  .  =  .  = . = . p = .
Moderate (3.2-5.1) N = 11 [18.3%] N=10[21.3%] N=11[32.4%] p = 0.29
PSL use N=52[86.7%] N=42[89.4%] N=30[88.2%] p = 0.91
PSL>5mg N=30 [50.0%] N=25[53.2%] N=17 [50.0%] p = 0.94
Baseline characteristics, including age, gender, duration of disease at baseline, DAS28-ESR
at baseline, distribution of DAS28-ESR and prednisoline use at intiation were not different
among MTX cotherapy, Non-MTX DMARDs cotherapy and etanercept monotherapy groups
except for the slight difference of age at entry. 
The distribution is characterized by Kruskal-Wallis test as described in the text.
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